Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Marquez-Rodas, I; Algarra, SM; Izquierdo, JAA; Cabello, SC; Martin, M.

A new era in the treatment of melanoma: from biology to clinical practice

CLINICAL & TRANSLATIONAL ONCOLOGY. 2011; 13(11): 787-792 Nº de citas: 9 [doi:10.1007/s12094-011-0734-6]

Martin, M; Romero, A; Cheang, MCU; Garcia-Asenjo, JA; Garcia-Saenz, JA; Oliva, B; Roman, JM; He, X; Casado, A; de la Torre, J; Furio, V; Puente, J; Caldes, T; Vidart, JA; Lopez-Tarruella, S; Diaz-Rubio, E; Perou, CM.

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

BREAST CANCER RESEARCH AND TREATMENT. 2011; 128(1): 127-136 Nº de citas: 65 [doi:10.1007/s10549-011-1461-y]

Bourgier, C; Calvo, FA; Marsiglia, H; Martin, M.

Overview of preoperative radiochemotherapy in breast cancer: past or future?

CLINICAL & TRANSLATIONAL ONCOLOGY. 2011; 13(7): 446-450 Nº de citas: 7 [doi:10.1007/s12094-011-0681-2]

Sierra-Filardi, E; Puig-Kroger, A; Blanco, FJ; Nieto, C; Bragado, R; Palomero, I; Bernabeu, C; Vega, MA; Corbi, AL.

Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers

BLOOD. 2011; 117(19): 5092-5101 Nº de citas: 247 [doi:10.1182/blood-2010-09-306993]

Romero, A; Martin, M; Cheang, MCU; Garcia-Asenjo, JAL; Oliva, B; He, XP; de la Hoya, M; Saenz, JAG; Fernandez, MA; Rubio, ED; Perou, CM; Llopis, TC.

Assessment of Topoisomerase II alpha Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization

AM J PATHOL. 2011; 178(4): 1453-1460 Nº de citas: 73 [doi:10.1016/j.ajpath.2010.12.042]

Caronia, D; Martin, M; Sastre, J; de la Torre, J; Garcia-Saenz, JA; Alonso, MR; Moreno, LT; Pita, G; Diaz-Rubio, E; Benitez, J; Gonzalez-Neira, A.

A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

CLINICAL CANCER RESEARCH. 2011; 17(7): 2006-2013 Nº de citas: 78 [doi:10.1158/1078-0432.CCR-10-1741]

Martin, M; Roche, H; Pinter, T; Crown, J; Kennedy, MJ; Provencher, L; Priou, F; Eiermann, W; Adrover, E; Lang, I; Ramos, M; Latreille, J; Jagiello-Gruszfeld, A; Pienkowski, T; Alba, E; Snyder, R; Almel, S; Rolski, J; Munoz, M; Moroose, R; Hurvitz, S; Banos, A; Adewoye, H; Hei, YJ; Lindsay, MA; Rupin, M; Cabaribere, D; Lemmerick, Y; Mackey, JR.

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

LANCET ONCOLOGY. 2011; 12(4): 369-376 Nº de citas: 76 [doi:10.1016/S1470-2045(11)70037-7]

Valero, V; Forbes, J; Pegram, MD; Pienkowski, T; Eiermann, W; von Minckwitz, G; Roche, H; Martin, M; Crown, J; Mackey, JR; Fumoleau, P; Rolski, J; Mrsic-Krmpotic, Z; Jagiello-Gruszfeld, A; Riva, A; Buyse, M; Taupin, H; Sauter, G; Press, MF; Slamon, DJ.

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

JOURNAL OF CLINICAL ONCOLOGY. 2011; 29(2): 149-156 Nº de citas: 198 [doi:10.1200/JCO.2010.28.6450]